New trial aims to find best treatment order for rare lymphoma
NCT ID NCT06314334
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with early-stage natural killer/T-cell lymphoma, a rare and aggressive cancer often linked to EBV. It compares three different sequences of chemotherapy, immunotherapy, and radiation to see which one keeps the cancer from coming back for at least two years. About 210 participants will be randomly assigned to one of the three treatment plans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital of Fujian Province
RECRUITINGFuzhou, Fujian, 350003, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
Nantong Cancer Hospital
RECRUITINGNantong, Jiangsu, 226006, China
-
People's Hospital of Ningbo University
RECRUITINGNingbo, Zhejiang, China
-
Shanghai Eye Ear Nose and Throat Hospital，Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200000, China
-
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200092, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.